SAN FRANCISCO–(BUSINESS WIRE)–InterVenn Biosciences, the leader in glycoproteomics, today announced Aldo Carrascoso, the company’s CEO and Co-Founder, is scheduled to present at the J.P. Morgan 40th Annual Healthcare Conference on January 12, 2022, from 3:00 – 3:25 pm EST. Mr. Carrascoso will provide a company overview of InterVenn and its first-of-its-kind glycoproteomics solutions.
Following the company presentation, management will participate in a virtual breakout session. InterVenn management will also participate in one-on-one meetings with investors, analysts, and other interested parties during the conference.
InterVenn Biosciences has developed a proprietary glycoproteomic biomarker discovery and interrogation platform based on artificial intelligence-empowered mass spectrometry for next-gen precision medicine. The company is working on developing novel predictive tests in a range of indications, including ovarian, pancreatic, liver, prostate, lung, kidney and other cancers, as well as on tests for treatment response prediction and monitoring of treatment efficacy, and disease progression. https://intervenn.com